Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
Reneo Pharmicals第四季度GAAP每股收益美元（0.70）未达到预期（0.62）；现金、现金等价物和短期投资为1.03亿美元
Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.62) by 12.9 percent. This is a 25 percent decrease over losses of $(0.56) per share from the same period last year.
Reneo Pharmicals（纳斯达克股票代码：RPHM）公布的季度亏损为每股0.70美元，比分析师普遍预期的0.62美元（0.62美元）低12.9％。这比去年同期每股亏损0.56美元（0.56美元）下降了25％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。